Compass therapeutics reports 2024 third quarter financial results and provides corporate update

Boston, nov. 12, 2024 (globe newswire) -- compass therapeutics, inc. (nasdaq: cmpx), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported third quarter 2024 financial results and provided a business update.

CMPX Ratings Summary

CMPX Quant Ranking